HIV drug resistance to integrase inhibitors in low- and middle-income countries.
作者信息
Fokam Joseph, Inzaule Seth, Colizzi Vittorio, Perno Carlo-Federico, Kaseya Jean, Ndembi Nicaise
机构信息
Chantal BIYA International Reference Centre for research on HIV/AIDS prevention and management, Yaoundé, Cameroon.
Faculty of Health Sciences, University of Buea, Buea, Cameroon.
出版信息
Nat Med. 2024 Mar;30(3):618-619. doi: 10.1038/s41591-023-02763-0.
Abstract
摘要
相似文献
1
HIV drug resistance to integrase inhibitors in low- and middle-income countries.低收入和中等收入国家中人类免疫缺陷病毒对整合酶抑制剂的耐药性
Nat Med. 2024 Mar;30(3):618-619. doi: 10.1038/s41591-023-02763-0.
2
Transmission of S230R integrase drug resistance mutation affecting second-generation integrase inhibitors in a French primary HIV-1 infected man.一名法国原发性HIV-1感染男性中影响第二代整合酶抑制剂的S230R整合酶耐药性突变的传播
J Antimicrob Chemother. 2023 Jul 5;78(7):1802-1803. doi: 10.1093/jac/dkad135.
3
Predictive Efficacy of Dual Therapies Combining Integrase Strand Transfer Inhibitors with Second-Generation Non-Nucleoside Reverse Transcriptase Inhibitors Following HIV-1 Treatment Failure in Cameroon: Implications for the Use of a Long-Acting Therapeutic Strategy in Low- and Middle-Income Countries.喀麦隆HIV-1治疗失败后整合酶链转移抑制剂与第二代非核苷类逆转录酶抑制剂联合双重疗法的预测疗效：对低收入和中等收入国家长效治疗策略应用的启示
Viruses. 2024 Nov 29;16(12):1853. doi: 10.3390/v16121853.
4
[Integrase inhibitors - new challenges for the treatment of HIV-1 infections].[整合酶抑制剂——治疗HIV-1感染的新挑战]
Med Monatsschr Pharm. 2013 Dec;36(12):448-59; quiz 461-2.
5
Is resistance to dolutegravir possible when this drug is used in first-line therapy?当多替拉韦用于一线治疗时，是否有可能出现对它的耐药性？
Viruses. 2014 Aug 27;6(9):3377-85. doi: 10.3390/v6093377.
6
Mutations in the HIV-1 3'-Polypurine Tract Can Confer Dolutegravir Resistance.HIV-1 3'-多聚嘌呤序列中的突变可导致对多替拉韦产生耐药性。
Antimicrob Agents Chemother. 2022 Jan 18;66(1):e0102721. doi: 10.1128/AAC.01027-21. Epub 2021 Oct 11.
7
What if HIV were unable to develop resistance against a new therapeutic agent?如果 HIV 无法对新的治疗药物产生耐药性，会怎样？
BMC Med. 2013 Nov 22;11:249. doi: 10.1186/1741-7015-11-249.
8
High performance of integrase genotyping on diverse HIV-1 clades circulating in Cameroon: toward a successful transition to dolutegravir-based regimens in low and middle-income countries.在喀麦隆流行的不同 HIV-1 亚型中整合酶基因分型的高性能：向中低收入国家成功过渡到基于多替拉韦的治疗方案。
Diagn Microbiol Infect Dis. 2022 Feb;102(2):115574. doi: 10.1016/j.diagmicrobio.2021.115574. Epub 2021 Oct 22.
9
Characterization of the Drug Resistance Profiles of Integrase Strand Transfer Inhibitors in Simian Immunodeficiency Virus SIVmac239.猿猴免疫缺陷病毒SIVmac239中整合酶链转移抑制剂耐药谱的特征分析
J Virol. 2015 Dec;89(23):12002-13. doi: 10.1128/JVI.02131-15. Epub 2015 Sep 16.
10
Primary resistance to integrase inhibitors in Shenzhen.深圳地区对整合酶抑制剂的原发性耐药情况。
J Antimicrob Chemother. 2023 Feb 1;78(2):546-549. doi: 10.1093/jac/dkac442.
引用本文的文献
1
Confronting Dual Therapeutic Hurdles in Advanced HIV: A Case Report on INSTIs Resistance and Talaromyces marneffei Coinfection.应对晚期艾滋病的双重治疗障碍：一例关于整合酶链转移抑制剂耐药与马尔尼菲篮状菌合并感染的病例报告
Int Med Case Rep J. 2025 Aug 22;18:1071-1075. doi: 10.2147/IMCRJ.S537404. eCollection 2025.
2
Do we need routine integrase resistance testing before starting antiretroviral therapy?在开始抗逆转录病毒治疗之前，我们是否需要进行常规的整合酶耐药性检测？
Lancet HIV. 2025 Jun 17. doi: 10.1016/S2352-3018(25)00108-0.
3
Treatment of Advanced HIV in the Modern Era.现代时代晚期HIV的治疗
Drugs. 2025 May 12. doi: 10.1007/s40265-025-02181-1.
4
The cumulative prevalence of HIV-1 drug resistance in perinatal HIV.围产期感染艾滋病毒中HIV-1耐药性的累积患病率。
AIDS. 2025 Jul 15;39(9):1161-1177. doi: 10.1097/QAD.0000000000004202. Epub 2025 Apr 15.
5
Brief communication: virological outcomes and dolutegravir resistance mutations in HIV-infected patients: a multicenter retrospective cohort study in Mozambique.简短通讯：HIV 感染患者的病毒学转归及多替拉韦耐药突变：莫桑比克的一项多中心回顾性队列研究
AIDS Res Ther. 2025 Jan 30;22(1):8. doi: 10.1186/s12981-025-00708-w.
6
Dolutegravir/Lamivudine Efficacy and Safety Outcomes in People With HIV-1 With or Without Historical Resistance Results at Screening: 48-Week Pooled Analysis.多替拉韦/拉米夫定在筛查时有或无既往耐药结果的HIV-1感染者中的疗效和安全性结局：48周汇总分析
Open Forum Infect Dis. 2024 Jul 1;11(7):ofae365. doi: 10.1093/ofid/ofae365. eCollection 2024 Jul.
本文引用的文献
1
HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysis.基于多替拉韦的抗逆转录病毒治疗患者中的 HIV-1 耐药性：一项协作队列分析。
Lancet HIV. 2023 Nov;10(11):e733-e741. doi: 10.1016/S2352-3018(23)00228-X. Epub 2023 Oct 10.
2
Treatment Emergent Dolutegravir Resistance Mutations in Individuals Naïve to HIV-1 Integrase Inhibitors: A Rapid Scoping Review.初治人类免疫缺陷病毒 1 型整合酶抑制剂人群中出现的治疗中出现的多替拉韦耐药突变：快速范围界定综述。
Viruses. 2023 Sep 15;15(9):1932. doi: 10.3390/v15091932.
3
The G118R plus R263K Combination of Integrase Mutations Associated with Dolutegravir-Based Treatment Failure Reduces HIV-1 Replicative Capacity and Integration.G118R 加上 R263K 整合酶突变组合与基于多替拉韦的治疗失败相关，降低了 HIV-1 的复制能力和整合。
Antimicrob Agents Chemother. 2023 May 17;67(5):e0138622. doi: 10.1128/aac.01386-22. Epub 2023 Apr 18.
4
First case of Dolutegravir and Darunavir/r multi drug-resistant HIV-1 in Cameroon following exposure to Raltegravir: lessons and implications in the era of transition to Dolutegravir-based regimens.喀麦隆首例拉替拉韦暴露后多药物耐药 HIV-1 型病毒（达芦那韦/利托那韦）：在向基于多替拉韦方案过渡时代的经验与启示。
Antimicrob Resist Infect Control. 2020 Aug 26;9(1):143. doi: 10.1186/s13756-020-00799-2.
5
Failure of Dolutegravir First-Line ART with Selection of Virus Carrying R263K and G118R.多替拉韦一线抗逆转录病毒治疗失败并出现携带R263K和G118R的病毒株
N Engl J Med. 2019 Aug 29;381(9):887-889. doi: 10.1056/NEJMc1806554.
6
Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research.多替拉韦用于中低收入国家的一线抗逆转录病毒治疗：实施和研究的不确定性和机遇。
Lancet HIV. 2018 Jul;5(7):e400-e404. doi: 10.1016/S2352-3018(18)30093-6. Epub 2018 Jun 5.
7
Development of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitors.在改用多替拉韦单药治疗后，HIV-1整合酶中出现G118R突变，导致对整合酶抑制剂产生交叉耐药。
J Antimicrob Chemother. 2016 Jul;71(7):1948-53. doi: 10.1093/jac/dkw071. Epub 2016 Mar 29.
Zotero 插件